Record title

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

Record identifier

TN_cdi_doaj_primary_oai_doaj_org_article_e9995b5c481945709e7709fd5db97be9

https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e9995b5c481945709e7709fd5db97be9

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

About this item

Full title

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

Publisher

England: BMJ Publishing Group LTD

Journal title

Journal for immunotherapy of cancer, 2021, Vol.9 (7), p.e002447

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_e9995b5c481945709e7709fd5db97be9

Language

English

Formats

Publication information

Publisher

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_e9995b5c481945709e7709fd5db97be9

Permalink

https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e9995b5c481945709e7709fd5db97be9

Other Identifiers

ISSN

E-ISSN

DOI

How to access this item